Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

NCT01910571
View directory record Official record
Conditions
Healthy
Interventions
P7435, Placebo
Drug · Other
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying

NCT00685477
View directory record Official record
Conditions
Healthy
Interventions
Experimental Sequence ABC, Experimental Sequence ACB, Experimental Sequence BAC, Experimental Sequence BCA, Experimental Sequence CAB, Experimental Sequence CBA
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

NCT01414075
View directory record Official record
Conditions
Dialysis, Anemia
Interventions
Roxadustat, Oral Iron, IV Iron
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Northridge, California • Yuba City, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 25, 2026, 5:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

NCT01688492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

NCT00023244
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 20 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma

NCT00470275
View directory record Official record
Conditions
Sarcoma
Interventions
cytarabine
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
63
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 25, 2026, 5:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oral Metformin for Treatment of ABCA4 Retinopathy

NCT04545736
View directory record Official record
Conditions
ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration
Interventions
Metformin hydrochloride
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Recruiting Phase 4 Interventional

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

NCT04588077
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Interventions
Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen
Biological
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

NCT01048619
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Not applicable Interventional

Melatonin in Pediatric FD Population

NCT04684199
View directory record Official record
Conditions
Dyspepsia
Interventions
Melatonin, Placebo
Dietary Supplement
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.

NCT00687830
View directory record Official record
Conditions
Colon Cancer
Interventions
Polyethylene Glycol afternoon, Polyethylene Glycol morning
Drug
Lead sponsor
Cleveland Clinic Florida
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

NCT05077098
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
ADXS-504
Drug
Lead sponsor
Mark Stein
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Ultrasound-induced Anti-inflammation in Human Subjects

NCT05685108
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ultrasound stimulation intensity, Ultrasound stimulation site
Device
Lead sponsor
University of Virginia
Other
Eligibility
25 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Early Phase 1 Interventional

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02405078
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TAS-120 in Patients With Advanced Solid Tumors

NCT02052778
View directory record Official record
Conditions
Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer
Interventions
Futibatinib
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
26
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 25, 2026, 5:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 25, 2026, 5:18 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ongoing Lung Decline With Age Intensified Response

NCT07676435
View directory record Official record
Conditions
Age-Related Lung Function Decline
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

NCT01721317
View directory record Official record
Conditions
Seizures
Interventions
Ezogabine/Retigabine IR, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
9
States / cities
Fresno, California • Santa Monica, California • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 25, 2026, 5:18 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

NCT00505414
View directory record Official record
Conditions
Pain, Neoplasm, Cancer
Interventions
Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase, Tapentadol in the Maintenance Phase, Morphine in the Titration Phase
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
St. Petersburg, Florida • Elkhart, Indiana • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 25, 2026, 5:18 AM EDT
Completed No phase listed Observational

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

NCT04848584
View directory record Official record
Conditions
COVID-19
Interventions
Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 25, 2026, 5:18 AM EDT
Withdrawn Phase 2 Interventional

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

NCT02628704
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Placebo (for selinexor), carfilzomib, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
West Hollywood, California • Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

NCT02597478
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Sublingual Spray, Shuttle Walk Test, Questionnaires, Mental Ability Tests, Phone Call
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

MR Image Synthesis With Low Gadobutrol Dose and AI

NCT06224543
View directory record Official record
Conditions
Enhancing Brain Lesions
Interventions
SubtleGAD, Gadobutrol
Device · Drug
Lead sponsor
Subtle Medical
Industry
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Peoria, Illinois • Worcester, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

NCT02497404
View directory record Official record
Conditions
Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
Interventions
5-Azacytidine, Fludarabine, Melphalan, Alemtuzumab, Total Body Irradiation
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 25, 2026, 5:18 AM EDT